The European Commission (EC) has granted Leqembi (lecanemab) Marketing Authorisation (MA) in the European Union (EU). 

The approval makes the medicine the first therapy that targets an underlying cause of Alzheimer’s disease (AD) to be granted a MA in the EU. 

Lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to AD (early AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology. 

“Today’s decision makes lecanemab the first treatment option in the European Union that can slow the progression of early Alzheimer’s disease and is a key step to making the medicine available to eligible patients. This is important news for those in the clinical and research Alzheimer’s community who are dedicated to improving the management of a disease which poses a significant burden to healthcare systems and society,” said Gary Hendler, Regional Chairman and CEO, Eisai EMEA, Senior Vice President & Global Corporate Officer, Eisai. 

Lecanemab is an amyloid-beta (Aβ) monoclonal antibody that preferentially binds and clears toxic protofibrils (soluble Aβ aggregates), in addition to targeting and reducing Aβ plaques (insoluble Aβ aggregates). 

A milestone in Alzheimer’s treatment

Eisai serves as the lead for lecanemab’s development and regulatory submissions globally, with both Eisai and Biogen co-commercialising and co-promoting the product, and Eisai having final decision-making authority. 

“The European Commission’s authorisation of lecanemab represents a significant milestone in addressing this progressive disease,” said Wolfram Schmidt, President and Head of Europe at Biogen. “We are proud there is now an approved treatment in the European Union that can slow the progression of early Alzheimer’s disease.” 

The EC authorisation was primarily based on Phase III data from Eisai’s Clarity AD clinical trial, in which the medicine met its primary endpoint (change from baseline in the Clinical Dementia Rating Sum of Boxes at 18 months). 

A new study by scientists in the UK and Belgium into four Alzheimer’s treatments found that lecanemab performed best in binding to small oligomeric forms of the amyloid protein, suggesting it works best in the earlier stages of disease, and could bind at more sites per aggregate. 

However, in a recent review article, published in the British Journal for Clinical Pharmacology, researchers from the UK’s Drug Safety Research Unit discuss the need for ongoing assessment of the safety and effectiveness of lecanemab in the real-world clinical setting in the UK and beyond.

Diana Spencer, Senior Digital Content Editor, DDW